Scisparc issued canadian patent for opioids reduction use in pain management technology

Tel aviv, israel, march 06, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment (the “patent”).
SPRC Ratings Summary
SPRC Quant Ranking